Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [0.03%]
初治HIV-1感染者接受艾比妥格拉韦/哥匹西拉/恩曲他滨/替诺福韦阿拉芬酰胺治疗48周后罕见出现耐药性
Nicolas A Margot,Kathryn M Kitrinos,Marshall Fordyce et al.
Nicolas A Margot et al.
Tenofovir alafenamide (TAF), a novel prodrug of the NtRTI tenofovir (TFV), delivers TFV-diphosphate (TFV-DP) to target cells more efficiently than the current prodrug, tenofovir disoproxil fumarate (TDF), with a 90% reduction in TFV plasma ...
Clinical Trial
HIV clinical trials. 2016 Mar;17(2):78-87. DOI:10.1080/15284336.2016.1142731 2016
Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents [0.03%]
替更公告. 马拉韦 roc与对照剂联用抗逆转录病毒药物治疗HIV-1及丙型肝炎和/或乙肝患者的肝脏安全性：一项随机双盲研究
Jùrgen K Rockstroch,Vicente Soriano,Frank Plonski et al.
Jùrgen K Rockstroch et al.
Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy [0.03%]
慢性HIV-1感染且接受稳定抗逆转录病毒治疗的成人血清淀粉样P(SAP)与尺动脉内皮功能障碍相关
Nath Zungsontiporn,Lishomwa C Ndhlovu,Brooks I Mitchell et al.
Nath Zungsontiporn et al.
Objective: This study aimed to evaluate the relationship between inflammatory biomarkers and endothelial dysfunction (ED), as measured by brachial artery flow-mediated dilation (FMD). ...
Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy [0.03%]
HIV-1慢性感染并接受稳定抗逆转录病毒治疗的成人外周血中SERUMAMYLOIDP(SAP)与上臂动脉流介导的扩张功能障碍相关
Nath Zungsontiporn,Lishomwa C Ndhlovu,Brooks I Mitchell et al.
Nath Zungsontiporn et al.
Objective: This study aimed to evaluate the relationship between inflammatory biomarkers and endothelial dysfunction (ED), as measured by brachial artery flow-mediated dilation (FMD). ...
Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis [0.03%]
溃疡性结肠炎患者使用美沙拉嗪治疗后HIV感染者血浆sCD14和I-FABP水平降低
Zuleika Michelini,Silvia Baroncelli,Alessandra Fantauzzi et al.
Zuleika Michelini et al.
Background: Microbial translocation (MT) is a shared feature of HIV infection and inflammatory bowel disease (IBD). Aims: This study wa...
Clinical Trial
HIV clinical trials. 2016 Mar;17(2):49-54. DOI:10.1080/15284336.2015.1125077 2016
Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia [0.03%]
人免疫缺陷病毒(HIV)感染伴脂代谢紊乱患者从依非韦伦换用利匹韦林后的血脂改善作用研究
Pornpimol Thamrongwonglert,Ploenchan Chetchotisakd,Siriluck Anunnatsiri et al.
Pornpimol Thamrongwonglert et al.
Rilpivirine (RPV) is a non-nucleoside reverse transcriptase inhibitor, which has better lipid profiles than efavirenz (EFV) in treatment naïve patients. However, the data on treatment experience are limited especially in dyslipidemic HIV p...
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [0.03%]
接受利托那韦增强的蛋白酶抑制剂加上两种核苷/核苷酸逆转录酶抑制剂治疗并获得病毒学抑制的 HIV-1 感染者中评估含有拉替拉韦和 darunavir/利托那韦的复方制剂的有效性及安全性：一项随机、开放标签 48 周非劣效性临床试验
Leonardo Calza,Ilaria Danese,Eleonora Magistrelli et al.
Leonardo Calza et al.
Background: Nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapies may be useful in HIV-infected patients with resistance or intolerance to this class. ...
Measuring the potential role of frailty in apparent declining efficacy of HIV interventions [0.03%]
测量脆弱性在似乎不断降低的HIV干预效力中的潜在作用
Felicia P Hardnett,Charles E Rose
Felicia P Hardnett
Objective: In recent HIV intervention trials, intervention efficacies appear to decline over time. Researchers have attributed this to "waning," or a loss of intervention efficacy. Another possible reason is heterogeneity...
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US [0.03%]
基于信息价值的HIV疗效比较试验优先级确定：美国的仿制ART与品牌名ART
Pamela P Pei,Milton C Weinstein,X Cynthia Li et al.
Pamela P Pei et al.
Background: Value of Information (VOI) analysis examines whether to acquire information before making a decision. We introduced VOI to the HIV audience, using the example of generic antiretroviral therapy (ART) in the US....
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US [0.03%]
基于信息价值的HIV比较效果试验优先级：美国的通用名药物与品牌名药物孰优孰劣
Pamela P Pei,Milton C Weinstein,X Cynthia Li et al.
Pamela P Pei et al.
Background: Value of Information (VOI) analysis examines whether to acquire information before making a decision. We introduced VOI to the HIV audience, using the example of generic antiretroviral therapy (ART) in the US....